Erratum: Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio". Focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids (Herz (2004) 29 (673-685) DOI: 10.1007/s00059-004-2602-4);Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio": Focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids

Herz

Volumn 29, Issue 7, 2004, Pages 673-685

  Rupp, Heinz ^a,b   Wagner, Daniela ^a   Rupp, Thomas ^a   Schulte, Lisa Maria ^a   Maisch, Bernhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Molecular Cardiology Laboratory   (Germany)

Author keywords

DHA; EPA; Omacor ; Omega 3 fatty acids; Sudden cardiac death

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CYTOKINE; DOCOSAHEXAENOIC ACID; ETOMOXIR; FENOFIBRATE; FISH OIL; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ARTICLE; CORONARY ARTERY DISEASE; DIETARY INTAKE; FATTY ACID TRANSPORT; FISH; GAS CHROMATOGRAPHY; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HUMAN; NONHUMAN; RISK ASSESSMENT; SUDDEN DEATH;

EID: 11244328984     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2602-4     Document Type: Erratum

References (79)

1. Ait-Said F, Elalamy I, Werts C, et al. Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MARK pathway. Biochim Biophys Acta 2003;1631:77-84.
2. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8.
3. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9.
4. Al Makdessi S, Brandle M, Ehrt M, et al. Myocardial protection by ischemic preconditioning: the influence of the composition of myocardial phospholipids. Mol Cell Biochem 1995;145:69-73.
5. Au D von, Brandle M, Rupp H, et al. Influence of a diet rich in fish oil on blood pressure, body weight and cardiac hypertrophy in spontaneously hypertensive rats. Eur J Appl Physiol 1988;58:97-9.
6. Barger PM, Brandt JM, Leone TC, et al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest 2000;105:1723-30.
7. Berge RK, Madsen L, Vaagenes H, et al. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J 1999;343:191-7.
8. Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000;148:387-96.
9. Chambrier C, Bastard JP, Rieusset J, et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res 2002;10:518-25.
10. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gam ma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80.
11. Cleland JG, Freemantle N, Kaye G, et al. Clinical trials update from the American Heart Association meeting: omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 2004;6:109-15.
12. Delerive P, De Bosscher K, Besnard S, et al. Peroxisomeproliterator- activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-54.
13. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
14. Diep ON, Amiri F, Touyz RM, et al. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002;40:866-71.
15. Donadio JV Jr, Larson TS, Bergstralh EJ, et al. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001;12:791-9.
16. Dotevall A, Johansson S, Wilhelmsen L, et al. Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA*study. Diabet Med 2004;21:615-22.
17. Eickhorn R, Isensee H, Jacob R, et al. No obvious influence of dietary fatty acid intake on cardiac sodium current of the rat. Pflugers Arch 1992;420:Suppl 1:334.
18. Emilsson A, Gudbjarnason S. Reversible alterations in fatty acid profile of glycerophospholipids in rat heart muscle induced by repeated norepinephrineadministration. Biochim Biophys Acta 1983;750:1-6.
19. Fischer S, Weber PC. Thromboxane (TX)A3 and prostaglandin (PG)I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry. Biomed Mass Spectrom 1985;12:470-6.
20. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997;94:4312-7.
21. Franz MR, Cima R, Wang D, et al. Electrophysiological effects of myocardial streich and mechanical determinants of stretch-activated arrhythmias. Circulation 1992;86:968-78.
22. Gerster H. Can adults adequately convert alpha-linolenic acid (18:ω-3) to eicosapentaenoic acid (20:ω-3) and docosahexaenoic acid (22:ω-3)? Int J Vitam Nutr Res 1998;68:159-73.
23. GISSI-Prevenzione Investigators. Dietary supplementation with ω-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
24. Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003;108:2883-91.
25. Grynberg A, Ziegler D, Rupp H. Sympathoadrenergic overactivity and lipid metabolism. Cardiovasc Drugs Ther 1996:10:Suppl 1:223-30.
26. Guallar E, Hennekens CH, Sacks FM, et al. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. J Am Coll Cardiol 1995;25:387-94.
27. Guallar E, Sanz-Gallardo MI, van't Veer P, et al. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 2002;347:1747-54.
28. Holler C, Auinger M, Ulberth F, et al. Eicosanoid precursors: potential factors for atherogenesis in diabetic CAPD patients? Perit Dial Int 1996;16:Suppl 1: S250-3.
29. Hu FB, Cho E, Rexrode KM, et al. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003;107:1852-7.
30. Iemitsu M, Miyauchi T, Maeda S, et al. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 2002;283:H1750-60.
31. Ikeda I, Imasato Y, Nagao H, et al. Lymphatic transport of eicosapentaenoic and docosahexaenoic acids as triglyceride, ethyl ester and free acid, and their effect on cholesterol transport in rats. Life Sci 1993;52:1371-9.
32. Jacob R, Brändle M, Dierberger B, et al. Antihypertensive und kardioprotektive Effekte verschiedener Öldiäten. In: Ganten D, Mall G, Hrsg. Herz-Kreislauf-Regulation, Organprotektion und Organschäden. Stuttgart:Schattauer, 1991:25-46.
33. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:3435-85.
34. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
35. Jump DB. The biochemistry of ω-3 polyunsaturated fatty acids. J Biol Chem 2002;277:8755-8.
36. Kozak M, Krivan L, Semrad B. Circadian variations in the occurrence of ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2003;26:731-5.
37. Kramer HJ, Stevens J, Grimminger F, et al. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 1996;52:1211-7.
38. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
39. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-9.
40. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun 1988;152:328-35.
41. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun 1988;156:960-3.
42. Leaf A, Xiao YF, Kang JX, et al. Prevention of sudden cardiac death by ω-3 polyunsaturated fatty acids. Pharmacol Ther 2003;98:355-77.
43. Leng GC, Taylor GS, Lee AJ, et al. Essential fatty acids and cardiovascular disease: the Edinburgh Artery Study. Vasc Med 1999;4:219-26.
44. Luley C, Wieland H, Grünwald J. Bioavailability of omega-3 fatty acids: ethylester preparations are as suitable as triglyceride preparations. Akt Ernährungsmed 1990;15:123-5.
45. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001;22:2085-103.
46. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by ω-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903.
47. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78.
48. Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000;164:6503-8.
49. Marx N, Sukhova GK, Collins T, et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31.
50. McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 2001;36:Suppl:S111-4.
51. Mensink GB, Thamm M, Haas K. [Nutrition in Germany 1998.] Gesundheitswesen 1999;61:S200-6.
52. Mirnikjoo B, Brown SE, Kim HF, et al. Protein kinase inhibition by omega-3 fatty acids. J Biol Chem 2001;276:10888-96.
53. Mozaffarian D, Lemaitre RN, Kuller LH, et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed:the Cardiovascular Health Study. Circulation 2003;107:1372-7.
54. Nair SS, Leitch J, Falconer J, et al. Cardiac (ω-3) non-esterified fatty acids are selectively increased in fish oil-fed pigs following myocardial ischemia. J Nutr 1999;129:1518-23.
55. Die Nationale Verzehrsstudie 1991. Bremerhaven: Wirtschaftsverlag NW, 1991.
56. Nilsen DW, Albrektsen G, Landmark K, et al. Effects of a high-dose concentrate of ω-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001;74:50-6.
57. Nilsen DW, Harris WS. ω-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2004;79:166.
58. Ohkubo T, Jacob R, Rupp H. Swimming changes vascular fatty acid composition and prostanoid generation of rats. Am J Physiol 1992;262:R464-71.
59. Pankuweit S, Portig I, Maisch B. Pathophysiology of cardiac inflammation: molecular mechanisms. Herz 2002;27:669-76.
60. Pater C, Compagnone D, Luszick J, et al. Effect of Omacor on HRV parameters in patients with recent uncomplicated myocardial infarction - a randomized, parallel group, double-blind, placebo-controlled trial: study design [IS-RCTN75358739]. Curr Control Trials Cardiovasc Med 2003;4:2.
61. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation 2002;105:2303-8.
62. Portilla D, Dai G, Peters JM, et al. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000;278:F667-75.
63. Robinson PJ, Noronha J, DeGeorge JJ, et al. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis. Brain Res Brain Res Rev 1992;17:187-214.
64. Rousseau D, Moreau D, Raederstorff D, et al. Is a dietary ω-3 fatty acid supplement able to influence the cardiac effect of the psychological stress? Mol Cell Biochem 1998;178:353-66.
65. Rupp H, Turcani M, Ohkubo T, et al. Dietary linolenic acid-mediated increase in vascular prostacyclin formation. Mol Cell Biochem 1996;162:59-64.
66. Rupp H, Verboom C-N, Jaeger B. Saving lives post-MI: highly purified omega-3 PUFAs for the prevention of sudden death. J Clin Basic Cardiol 2002;5:209-14.
67. Rupp H, Vetter R. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure. Br J Pharmacol 2000;131:1748-56.
68. Rupp H, Wahl R, Hansen M. Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum. J Appl Physiol 1992;72:352-60.
69. Schacky C von, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554-62.
70. Schacky C von, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985;76:2446-50.
71. Schrepf R, Limmert T, Weber PC, et al. Immediate effects of ω-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet 2004;363:1441-2.
72. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Am J Clin Nutr 2000:71:208-12.
73. Thies F, Garry JM, Yaqoob P, et al. Association of ω-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-85.
74. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
75. Verboom C-N, Marchioli R, Rupp H, et al. Highly purified omega-3 fatty acids for secondary prevention of post-myocardial infarction. London: Royal Society of Medicine Press, 2003.
76. Yli-Jama P, Meyer HE, Ringstad J, et al. Serum free fatty acid pattern and risk of myocardial infarction: a case-control study. J Intern Med 2002;251:19-28.
77. Yoshimura T, Matsui K, Ito M, et al. Effects of highly purified eicosapentaenoic acid on plasma beta thromboglobulin level and vascular reactivity to angiotensin II. Artery 1987;14:295-303.
78. Yusufi AN, Cheng J, Thompson MA, et al. Differential effects of low-dose docosahexaenoicacid and eicosapentaenoic acid on the regulation of mitogenic signaling pathways in mesangial cells. J Lab Clin Med 2003;141:318-29.
79. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 2002;11:345-56.